| Drug Type Antibody drug conjugate (ADC) | 
| Synonyms AVID 300, AVID300 | 
| Target | 
| Action antagonists, inhibitors | 
| Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Tubulin inhibitors | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC35H48ClN3O10S | 
| InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N | 
| CAS Registry139504-50-0 | 



| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Fibrosis | Preclinical | United States  | - | 






